MARK J SHLOMCHIK, MD
Medical Practice in New Haven, CT

2006022, Oct 5, 2006

Mar 17, 2006

11/377647

Warren Shlomchik - Westport CT, US
Mark Shlomchik - Woodbridge CT, US

A61K 35/14, A61K 48/00, A61K 39/02, A61K 36/47

424093700, 424133100, 424235100, 424731000, 424093210

The invention includes compositions and methods for depleting and/or inactivating antigen presenting cells, or for otherwise impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases.

2011019, Aug 4, 2011

Apr 3, 2009

12/418519

Chun-Nan Chen - San Jose CA, US
James O. Bowlby - San Jose CA, US
Richard Aleck Jorgensen - San Jose CA, US
Mark Jay Shlomchik - Woodbridge CT, US

C40B 30/04, C40B 40/06

506 9, 506 16

The invention is a methodology which makes it possible to select from a very large number of cells, a single cell or cells of interest and obtain specific information from those cells in a rapid and efficient manner. As an example of the methodology, a large number of antibody producing cells such as plasma cells are separated so that these individual antibody producing plasma cells are placed in individual wells. The cells are allowed to produce antibodies and the antibodies in the wells are then contacted with a protein bound to a solid surface such as a well top. The protein universally and specifically binds antibodies in the wells. The surface or well tray top includes addresses configured such that each address is specifically related to one of the individual wells containing a cell producing antibodies.

2010020, Aug 12, 2010

Nov 25, 2009

12/625815

Elizabeth A. Leadbetter - Roslindale MA, US
Ian R. Rifkin - Boston MA, US
Mark J. Shlomchik - Woodbridge CT, US

Trustees of Boston University - Boston MA
Yale University - New Haven CT

A61K 39/395, A61K 31/7088, A61K 38/16, G01N 33/53, A61P 37/06

4241351, 514 44 A, 514 12, 435 71, 435 724

The present invention provides methods and compositions for treating immune complex associated diseases (ICAD), such as SLE, rheumatoid arthritis, and hepatitis-C related immune complex disease (e.g., cryoglobulinemia) in a subject having an ICAD or at risk for developing ICAD. The invention is based upon the surprising finding that chromatin-containing immune complexes activate autoreactive B cells and dendritic cells by a dual receptor engagement process which, in both cell types, involves a Toll-like receptor (TLR). The methods of treating ICAD comprise administering a compound to an individual in need thereof that either 1) inhibits formation of the immune complex either by preventing formation and/or binding to the TLR, or 2) interferes with binding of an autoantigen-containing immune complex (or the antigenic component thereof) to the TLR, or 3) inhibits signaling pathways initiated by dual engagement of BCR and TLR (in B cells) or FcR and TLR (in dendritic cells) via immune complexed or uncomplexed autoantigens.

7709451, May 4, 2010

Sep 9, 2002

10/487885

Elizabeth A. Leadbetter - Roslindale MA, US
Ian R. Rifkin - Boston MA, US
Mark J. Shlomchik - Woodbridge CT, US

Trustees of Boston University - Boston MA
Yale University - New Haven CT

A61K 31/52, A61K 31/04

514 44, 4241441

The present invention provides methods and compositions for treating immune complex associated diseases (ICAD), such as SLE, rheumatoid arthritis, and hepatitis-C related immune complex disease (e. g. , cryoglobulinemia) in a subject having an ICAD or at risk for developing ICAD. The invention is based upon the surprising finding that chromatin-containing immune complexes activate autoreactive B cells and dendritic cells by a dual receptor engagement process which, in both cell types, involves a Toll-like receptor (TLR). The methods of treating ICAD comprise administering a compound to an individual in need thereof that either 1) inhibits formation of the immune complex either by preventing formation and/or binding to the TLR, or 2) interferes with binding of an autoantigen-containing immune complex (or the antigenic component thereof) to the TLR, or 3) inhibits signaling pathways initiated by dual engagement of BCR and TLR (in B cells) or FcR and TLR (in dendritic cells) via immune complexed or uncomplexed autoantigens.

7288255, Oct 30, 2007

May 11, 2000

09/568834

Warren D. Shlomchik - Stratford CT, US
Mark Jay Shlomchik - Woodbridge CT, US
Stephen G. Emerson - Wayne PA, US

Yale University - New Haven CT

A61K 39/395, A01N 63/00, C07K 16/00, C07K 17/00, C12P 21/08

4241831, 4241781, 424 937, 5303871, 5303873, 5303887, 5303917

The invention includes compositions and methods for depleting antigen presenting cells, or for impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases.